fda warns against compounded semaglutide issues warning about some versions of for diabetes, weight loss FDA warns consumers not to

But in August, The Washington Post reported the Trump administration was considering a five-year pilot program for Medicare and Medicaid to cover the drugs after all

The absence of nitrate interaction is a clinically useful property of PT-141 relative to PDE5 inhibitors

Health Risks and Ethical Concerns in Athletic Populations Semaglutide carries several risks that intensify in athletic settings

Ferroptosis: a double-edged sword mediating immune tolerance of cancer

The Indiana-based drugmaker raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter worldwide revenue rose 56% to $19.8 billion, driven by demand for Zepbound and its diabetes drug Mounjaro